Last quarter biotech attracted a whopping $1.8 billion in new venture cash, the biggest quarter since 2005.
U.S. biotech companies attracted a bountiful $1.3 billion venture haul in the fourth quarter of 2013, pushing the total for the year to $4.53 billion--well ahead of 2012's mark of $4.19 billion and a hopeful sign of continued activity headed into 2014.
In 2013, VCs spent $2.1 billion on 308 medical device investment deals, representing a 17% plunge in dollars and 4% drop in deals compared to the year before, according to the latest MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association, based on Thomson Reuters data.
There were a few misfires on the biotech IPO front in the fourth quarter of 2013, but the National Venture Capital Association says it tallied 6 newly minted public drug developers in the period, winding up a big year.
In this list of the top 10 med tech VC deals for Q3, one thing is painfully clear: Early-stage innovators are out of the picture. The winning companies are relatively far along, looking to expand...
An interesting thing happened on the way through 2013: Biotechnology venture investing began to see a healthy rebound in the second quarter, but medical device investing stayed essentially flat compared to the first three months of the year. Check out the report >>
Venture capital investment in medical device companies declined slightly during the 2013 second-quarter, even as it soared significantly for biotechnology and many other industries.
The VC industry turned in bleak numbers for biotech deal-making in the first quarter of 2013, with one key measure of early-stage activity in the life science sector falling to its lowest level in almost 18 years.
Med Tech venture investing continued its painful decline in the 2013 first quarter, dropping a whopping 20% in dollars and 10% in deal numbers versus last the three months of 2012, according to the latest MoneyTree survey.
In 2012, the medical device sector saw a 13% dollar-value drop from the year before and a 15% decline in the number of deals, according to the latest MoneyTree report. Read more >>